Conservative Management for PAS Pilot

Placenta Accreta Clinical Trial

Official title:

Conservative Management as an Alternative to Hysterectomy for Placenta Accreta Spectrum: a Pilot Randomized Controlled Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05139498
• Other study ID #: 144922
• Status: Recruiting
• Phase: N/A
• Start date: May 26, 2022
• Est. completion date: June 30, 2026

Study information

• Verified date: July 2023
• Source: University of Utah
• Contact: Ashley Joseph
• Phone: 801-903-3278
• Email: ashley.joseph[@]hsc.utah.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Conservative in situ management is a promising alternative treatment to hysterectomy for patients with placenta accreta spectrum and may be safer and preferable for some patients. This study will assess feasibility of a future randomized clinical trial comparing these treatments and provide novel data to inform shared decision-making and cost-effective care for patients with this deadly pregnancy disorder.

Description:

Placenta accreta spectrum (PAS) is an extremely morbid and increasingly common pregnancy condition that often results in massive obstetric hemorrhage. The standard treatment in the United States is hysterectomy, but this treatment is complex, morbid, and costly. A promising alternative for PAS treatment is conservative in situ management (CM), a strategy in which the placenta is left in the uterus. Unfortunately, there are insufficient data available to compare outcomes of these two treatments because past studies are limited by non-randomized study designs, minimal inclusion of patient values in making treatment decisions, and nominal consideration of economic barriers to care. A large clinical trial comparing PAS treatments is needed. But there are key logistic barriers to an adequately powered trial, including questions of whether patients will enroll and adhere to randomization allocation. This pilot trial will evaluate the feasibility of randomizing patients to CM versus hysterectomy for PAS. While pilot studies cannot make final assessments of safety and efficacy between interventions, safety and efficacy will be monitored, including those related to hemorrhage, transfusion, infection and re-operation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: June 30, 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Age 18 and older
• History of cesarean delivery AND placenta previa OR anterior low-lying placenta AND suspected of having PAS on prenatal imaging (ultrasound/MRI)
• Patients who would typically be recommended for hysterectomy
• Planned delivery between 34w0d and 36w0d gestation.

Exclusion Criteria:

• Plan to delivery before neonatal viability (<24 weeks gestation)
• Hospitalized for antenatal hemorrhage
• Have a low antenatal suspicion for PAS based on imaging
• Are pregnant with multiples (twins, triplets)
• Have a uterine fetal demise

Related Conditions & MeSH terms

• Placenta Accreta

Intervention

Procedure:
• Conservative management for placenta accreta spectrum (PAS)
Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
• Cesarean hysterectomy for placenta accreta spectrum (PAS)
Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together

Locations

Country	Name	City	State
United States	University of Utah	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients completing the surgical treatment to which they are allocated	Number of patients completing the surgical treatment to which they are allocated (hysterectomy or conservative management) on the day of delivery.	Day of delivery
Secondary	Number of eligible people approached for enrollment.	Number of eligible people approached for enrollment.	20 weeks gestation through day of delivery
Secondary	Number of eligible people randomized.	Number of eligible people randomized.	From time of consent up to one week (1-7 days) before planned delivery
Secondary	Number of enrolled completing hysterectomy on day of delivery.	Number of enrolled completing hysterectomy on day of delivery.	Day of delivery
Secondary	Number of enrolled completing conservative management on day of delivery.	Number of enrolled completing conservative management on day of delivery.	Day of delivery
Secondary	Number of enrolled who don't complete their allocated treatment (drop-out).	Number of enrolled who don't complete their allocated treatment (drop-out).	Up to 6 weeks postpartum
Secondary	Number of enrolled who are lost to follow-up through study end (inverse of retention).	Number of enrolled who are lost to follow-up through study end (inverse of retention).	Up to 6 weeks postpartum
Secondary	Number of enrolled completing full postpartum follow-up visit schedule.	Number of enrolled completing full postpartum follow-up visit schedule.	Up to 6 weeks postpartum